Goodpasture syndrome secondary prevention

Jump to navigation Jump to search

Goodpasture syndrome Microchapters


Patient Information


Historical Perspective




Differentiating Goodpasture syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray




Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Goodpasture syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Goodpasture syndrome secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Goodpasture syndrome secondary prevention

CDC on Goodpasture syndrome secondary prevention

Goodpasture syndrome secondary prevention in the news

Blogs on Goodpasture syndrome secondary prevention

Directions to Hospitals Treating Goodpasture syndrome

Risk calculators and risk factors for Goodpasture syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]


Effective measures for the secondary prevention of Goodpasture syndrome include patient education. Patients should be educated about the signs and symptoms of renal dysfunction as certain steroid and immunosuppressive therapy may have adverse effects on the kidneys. Patients should be monitored regularly for renal function and those with severe dysfunction should have be referred for dialysis.

Secondary Prevention

Effective measures for the secondary prevention of Goodpasture syndrome include:[1][2][3][4]

  • Patient education: Patient education is an important aspect in early diagnosis and management of Goodpasture syndrome.


  1. Kluth DC, Rees AJ (November 1999). "Anti-glomerular basement membrane disease". J. Am. Soc. Nephrol. 10 (11): 2446–53. PMID 10541306.
  2. Menn-Josephy H, Beck LH (2015). "Recurrent glomerular disease in the kidney allograft". Front Biosci (Elite Ed). 7: 135–48. PMID 25553369.
  3. "Notice". Kidney Int Suppl (2011). 2 (2): 139. 2012. doi:10.1038/kisup.2012.9. PMC 4089568. PMID 25028634.
  4. Chen M, Kallenberg CG (2010). "ANCA-associated vasculitides--advances in pathogenesis and treatment". Nat Rev Rheumatol. 6 (11): 653–64. doi:10.1038/nrrheum.2010.158. PMID 20924413.

Template:WH Template:WS